OS Therapies Incorporated (OSTX) Income Statement
OSTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOSTX revenue and net income
OSTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OSTX quarterly EPS vs estimates
OS Therapies beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.13).
OSTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $363,085 | $2,780 | $4,220 | $805 | $1.2M | $4,250 |
| Gross profit | −$363,085 | −$2,780 | −$4,220 | −$805 | −$1.2M | −$4,250 |
| Research & development | $16.36B | $2.8M | $3.2M | $3.3M | $2.2M | $602 |
| Sales, general & admin | $12.34B | $4.0M | $1.1M | $1.2M | $1.5M | $795 |
| Total operating expenses | $28.3M | $6.8M | $4.3M | $4.4M | $3.7M | $1,397 |
| Operating income | −$28.7M | −$6.8M | −$4.3M | −$4.4M | −$4.8M | −$5,647 |
| Interest income | $249 | $0 | $2 | $0 | — | — |
| Interest expense | $0 | $2.1M | $3.4M | $1.8M | $2.6M | $461.8M |
| Income before taxes | −$28.8M | −$8.9M | −$7.8M | −$6.3M | −$7.4M | −$6,027 |
| Net income | −$28.8M | −$8.9M | −$7.8M | −$6.3M | −$7.4M | −$6,027 |
| EBITDA | −$28.4M | −$6.8M | −$4.3M | −$4.4M | −$4.8M | $61,353 |
| EPS (diluted) | −$0.99 | −$0.98 | −$0.39 | −$0.63 | −$0.55 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $124,938 | $124,938 | $124,938 | $124,938 | $112,514 | $695 | $1,390 | — | $695 | $695 | — | $3,315 |
| Gross profit | −$124,938 | −$124,938 | −$124,938 | −$124,938 | −$112,514 | −$695 | −$1,390 | — | −$695 | −$695 | — | −$3,315 |
| Research & development | $6.07B | $7.2M | $16.35B | $3.8M | $2.5M | $1.3M | $869,079 | $1.2M | $396,567 | $361,809 | $1.0M | $451,190 |
| Sales, general & admin | $2.50B | $2.8M | $12.34B | $3.1M | $2.3M | $3.7M | $2.1M | $1.2M | $383,233 | $268,423 | $132,883 | $167,703 |
| Total operating expenses | $8.5M | $10.0M | $11.9M | $6.9M | $4.7M | $5.0M | $3.0M | $2.4M | $779,800 | $630,232 | $1.2M | $618,893 |
| Operating income | −$8.6M | −$10.2M | −$12.0M | −$6.9M | −$4.8M | −$5.0M | −$3.0M | −$2.4M | −$779,800 | −$630,232 | −$1.2M | −$622,208 |
| Interest income | $46 | $45 | $54 | $65 | $64 | $66 | $1 | $0 | $1 | $0 | $0 | $1 |
| Interest expense | $5,581 | $75,344 | $0 | $0 | $0 | $0 | $7,556 | $437,839 | $777,681 | $828,760 | $307,534 | $1.4M |
| Income before taxes | −$8.6M | −$10.4M | −$13.5M | −$6.9M | −$4.5M | −$3.9M | −$3.0M | −$2.9M | −$1.6M | −$1.5M | −$1.5M | −$2.0M |
| Net income | −$8.6M | −$10.4M | −$13.5M | −$6.9M | −$4.5M | −$3.9M | −$3.0M | −$2.9M | −$1.6M | −$1.5M | −$1.5M | −$2.0M |
| EBITDA | −$8.5M | −$10.2M | −$13.3M | −$6.8M | −$4.4M | −$3.9M | −$3.0M | −$2.1M | −$779,104 | −$629,537 | −$943,799 | −$618,892 |
| EPS (diluted) | −$0.20 | −$0.27 | −$0.41 | −$0.21 | −$0.19 | −$0.18 | −$0.19 | −$0.18 | −$0.61 | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OSTX's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OSTX financial results
OS Therapies reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $28.8 million. Diluted earnings per share came to −$0.99.
See the OSTX stock overview for the latest quote and news, or the OSTX chart for price history and technical indicators.
OSTX income statement FAQ
Does OS Therapies have revenue?
OS Therapies reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is OS Therapies profitable?
No. OS Therapies reported a net loss of $28.8 million in fiscal 2025.
How much does OS Therapies spend on research and development?
OS Therapies spent $16.4 billion on research and development in fiscal 2025.
What are OS Therapies's earnings per share?
OS Therapies earned $-0.99 per diluted share in fiscal 2025, compared with $-0.98 a year earlier.
When will OS Therapies report its next earnings?
OS Therapies is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does OS Therapies's fiscal year end?
OS Therapies's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.